Eli Lilly
Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire Ventyx Biosciences (NASDAQ:VTYX) for approximately $1.2 billion. The all-cash deal, valued at $14.00 per share, marks